About US
Contact us
-
Shire scores a patent victory for Lialda, but Bass-spurred PTO review loomsShire($SHPG) has scored a victory in its quest to protect its patent on ulcerative colitis med Lialda. Tuesday, it said the U.S. District Court for Southern Florida had upheld Lialda's IP shield, dete2016/3/30
-
In surprise decision, FDA blocks crucial cognitive claim for Takeda's BrintellixTheFDAdoesn't have to follow the advice of its expert review panels, but it usually does. That's a standard line in stories about advisory committee votes. Unfortunately forLundbeckandTakeda, their ne2016/3/30
-
Sanofi, Regeneron rack up some cost-savings data for their PCSK9 contender PraluentIt's not the cardiovascular outcomes data doctors and payers are waiting for, but it's outcomes data nonetheless. Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 contender Praluent helped patients with a2016/3/29
-
Merck's $200M damages in Gilead hep C case falls far short of expectationsMerck & Co. won ahepatitis Cpatent fight with Gilead Sciences last week, but if the jury's first damages award is any indication, the score could be much smaller than the $3 billion analysts had p2016/3/29
-
Arjuna Natural invests in research programme to explore benefits of turmericIndian botanical extracts manufacturer Arjuna Natural is investing $1.5m in a clinical research programme to explore the health benefits of its turmeric curcumin. The investment is more than 10% of i2016/3/28
-
The World's Smallest Cooling Circulators with 5.7in Touch ScreenMinistats are the world's smallest cooling circulators. Due to their compact dimensions, the units can be operated in confined spaces such as a laboratory fume cupboard or inside a technical plant.2016/3/28
-
Novartis wraps up China bribery probe with $25M payment to SECNovartis agreed to fork over $25 million to settle aSecurities and Exchange Commissioninvestigation into bribery allegations in China. It's the latest example of corruption claims made against the Swi2016/3/25
-
With Cinqair nod, Teva squares off with GSK in severe asthmaWatch out, GlaxoSmithKline--you've got more competition. Teva ($TEVA) wonFDAapproval Wednesday for its own biologic drug for severe asthma with eosinophilic inflammation, Cinqair. It'll join GSK's ($2016/3/25
-
Helsinn and Eisai extend partnership for prevention of CINVHelsinn and Eisai will continue to co-promote and distribute Aloxi (palonosetron HCl) injection for the prevention of chemotherapy-induced nausea and vomiting (CINV). The move comes as the companies2016/3/24
-
AstraZeneca to acquire rights to Orexo’s OX-CLI programmeAstraZeneca has announced plans to acquire all rights to Orexo´s leukotriene C4 synthase inhibitor programme, OX-CLI project, for $5m. The company partnered with Orexo AB for OX-CLI in 2013 and2016/3/24